{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T19:35:04Z","timestamp":1790969704439,"version":"4.1.0"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2017,6,22]],"date-time":"2017-06-22T00:00:00Z","timestamp":1498089600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arch Osteoporos"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1007\/s11657-017-0351-2","type":"journal-article","created":{"date-parts":[[2017,6,22]],"date-time":"2017-06-22T13:42:33Z","timestamp":1498138953000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":50,"title":["Factors associated with high 24-month persistence with denosumab: results of a real-world, non-interventional study of women with postmenopausal osteoporosis in Germany, Austria, Greece, and Belgium"],"prefix":"10.1007","volume":"12","author":[{"given":"A.","family":"Fahrleitner-Pammer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Papaioannou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Gielen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Feudjo Tepie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Toffis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Frieling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Geusens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Makras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Boschitsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Callens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. D.","family":"Anastasilakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Niedhart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Resch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Kalouche-Khalil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Hadji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,6,22]]},"reference":[{"key":"351_CR1","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1016\/S0140-6736(02)08657-9","volume":"359","author":"SR Cummings","year":"2002","unstructured":"Cummings SR, Melton LJ (2002) Epidemiology and outcomes of osteoporotic fractures. Lancet 359:1761\u20131767","journal-title":"Lancet"},{"key":"351_CR2","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1007\/s11657-013-0136-1","volume":"8","author":"E Hernlund","year":"2013","unstructured":"Hernlund E, Svedbom A, Ivergard M, Compston J, Cooper C, Stenmark J, McCloskey EV, Jonsson B, Kanis JA (2013) Osteoporosis in the European Union: medical management, epidemiology and economic burden. A report prepared in collaboration with the International Osteoporosis Foundation (IOF) and the European Federation of Pharmaceutical Industry Associations (EFPIA). Arch Osteoporos 8:136","journal-title":"Arch Osteoporos"},{"key":"351_CR3","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1007\/s11657-013-0137-0","volume":"8","author":"A Svedbom","year":"2013","unstructured":"Svedbom A, Hernlund E, Ivergard M, Compston J, Cooper C, Stenmark J, McCloskey EV, Jonsson B, Kanis JA, EU Review Panel of IOF (2013) Osteoporosis in the European Union: a compendium of country-specific reports. Arch Osteoporos 8:137","journal-title":"Arch Osteoporos"},{"key":"351_CR4","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1111\/j.1524-4733.2007.00213.x","volume":"11","author":"JA Cramer","year":"2008","unstructured":"Cramer JA, Roy A, Burrell A, Fairchild CJ, Fuldeore MJ, Ollendorf DA, Wong PK (2008) Medication compliance and persistence: terminology and definitions. Value Health 11:44\u201347","journal-title":"Value Health"},{"key":"351_CR5","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1007\/s00198-011-1535-z","volume":"23","author":"P Hadji","year":"2012","unstructured":"Hadji P, Claus V, Ziller V, Intorcia M, Kostev K, Steinle T (2012) GRAND: the German retrospective cohort analysis on compliance and persistence and the associated risk of fractures in osteoporotic women treated with oral bisphosphonates. Osteoporos Int 23:223\u2013231","journal-title":"Osteoporos Int"},{"key":"351_CR6","first-page":"25","volume":"3","author":"A Hoer","year":"2009","unstructured":"Hoer A, Seidlitz C, Gothe H, Schiffhorst G, Olson M, Hadji P, Haussler B (2009) Influence on persistence and adherence with oral bisphosphonates on fracture rates in osteoporosis. Patient Prefer Adherence 3:25\u201330","journal-title":"Patient Prefer Adherence"},{"key":"351_CR7","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1016\/j.bone.2005.10.022","volume":"38","author":"KF Huybrechts","year":"2006","unstructured":"Huybrechts KF, Ishak KJ, Caro JJ (2006) Assessment of compliance with osteoporosis treatment and its consequences in a managed care population. Bone 38:922\u2013928","journal-title":"Bone"},{"key":"351_CR8","first-page":"A567","volume":"16","author":"P Lakatos","year":"2013","unstructured":"Lakatos P, T\u00f3th E, Lang Z, Psachoulia E, Intorcia M (2013) Compliance protects against fracture in women with postmenopausal osteoporosis in Hungary. Value Health 16:A567","journal-title":"Value Health"},{"key":"351_CR9","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1016\/j.amjmed.2008.12.002","volume":"122","author":"ES Siris","year":"2009","unstructured":"Siris ES, Selby PL, Saag KG, Borgstrom F, Herings RM, Silverman SL (2009) Impact of osteoporosis treatment adherence on fracture rates in North America and Europe. Am J Med 122:S3\u201313","journal-title":"Am J Med"},{"key":"351_CR10","first-page":"24","volume":"14","author":"B Ettinger","year":"2005","unstructured":"Ettinger B (2005) Bisphosphonates: providing strength to a significant class. Manag Care 14:24\u201328","journal-title":"Manag Care"},{"key":"351_CR11","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/S0025-6196(11)60752-0","volume":"84","author":"KA Kennel","year":"2009","unstructured":"Kennel KA, Drake MT (2009) Adverse effects of bisphosphonates: implications for osteoporosis management. Mayo Clin Proc 84:632\u2013637 quiz 638","journal-title":"Mayo Clin Proc"},{"key":"351_CR12","doi-asserted-by":"crossref","first-page":"2010","DOI":"10.1016\/S0140-6736(06)68891-0","volume":"367","author":"P Sambrook","year":"2006","unstructured":"Sambrook P, Cooper C (2006) Osteoporosis. Lancet 367:2010\u20132018","journal-title":"Lancet"},{"key":"351_CR13","doi-asserted-by":"crossref","first-page":"2967","DOI":"10.1007\/s00198-016-3623-6","volume":"27","author":"P Hadji","year":"2016","unstructured":"Hadji P, Kyvernitakis I, Kann PH, Niedhart C, Hofbauer LC, Schwarz H, Kurth AA, Thomasius F, Schulte M, Intorcia M et al (2016) GRAND-4: the German retrospective analysis of long-term persistence in women with osteoporosis treated with bisphosphonates or denosumab. Osteoporos Int 27:2967\u20132978","journal-title":"Osteoporos Int"},{"key":"351_CR14","doi-asserted-by":"crossref","first-page":"2401","DOI":"10.1007\/s00198-015-3253-4","volume":"26","author":"L Karlsson","year":"2015","unstructured":"Karlsson L, Lundkvist J, Psachoulia E, Intorcia M, Strom O (2015) Persistence with denosumab and persistence with oral bisphosphonates for the treatment of postmenopausal osteoporosis: a retrospective, observational study, and a meta-analysis. Osteoporos Int 26:2401\u20132411","journal-title":"Osteoporos Int"},{"key":"351_CR15","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/s00223-015-0082-6","volume":"98","author":"P Lakatos","year":"2016","unstructured":"Lakatos P, Takacs I, Marton I, Toth E, Zoltan C, Lang Z, Psachoulia E, Intorcia M (2016) A retrospective longitudinal database study of persistence and compliance with treatment of osteoporosis in Hungary. Calcif Tissue Int 98:215\u2013225","journal-title":"Calcif Tissue Int"},{"key":"351_CR16","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1136\/jech.2008.084558","volume":"64","author":"MN Dugard","year":"2010","unstructured":"Dugard MN, Jones TJ, Davie MW (2010) Uptake of treatment for osteoporosis and compliance after bone density measurement in the community. J Epidemiol Community Health 64:518\u2013522","journal-title":"J Epidemiol Community Health"},{"key":"351_CR17","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1007\/s00198-007-0410-4","volume":"18","author":"F Lekkerkerker","year":"2007","unstructured":"Lekkerkerker F, Kanis JA, Alsayed N, Bouvenot G, Burlet N, Cahall D, Chines A, Delmas P, Dreiser RL, Ethgen D et al (2007) Adherence to treatment of osteoporosis: a need for study. Osteoporos Int 18:1311\u20131317","journal-title":"Osteoporos Int"},{"key":"351_CR18","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1592\/phco.28.4.437","volume":"28","author":"BA Briesacher","year":"2008","unstructured":"Briesacher BA, Andrade SE, Fouayzi H, Chan KA (2008) Comparison of drug adherence rates among patients with seven different medical conditions. Pharmacotherapy 28:437\u2013443","journal-title":"Pharmacotherapy"},{"key":"351_CR19","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1007\/s00774-013-0440-2","volume":"31","author":"JF Boven van","year":"2013","unstructured":"van Boven JF, de Boer PT, Postma MJ, Vegter S (2013) Persistence with osteoporosis medication among newly-treated osteoporotic patients. J Bone Miner Metab 31:562\u2013570","journal-title":"J Bone Miner Metab"},{"key":"351_CR20","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1016\/j.bone.2011.12.021","volume":"50","author":"SW Wade","year":"2012","unstructured":"Wade SW, Curtis JR, Yu J, White J, Stolshek BS, Merinar C, Balasubramanian A, Kallich JD, Adams JL, Viswanathan HN (2012) Medication adherence and fracture risk among patients on bisphosphonate therapy in a large United States health plan. Bone 50:870\u2013875","journal-title":"Bone"},{"key":"351_CR21","doi-asserted-by":"crossref","first-page":"2279","DOI":"10.1007\/s00198-014-2762-x","volume":"25","author":"SW Wade","year":"2014","unstructured":"Wade SW, Satram-Hoang S, Stolshek BS (2014) Long-term persistence and switching patterns among women using osteoporosis therapies: 24- and 36-month results from POSSIBLE US. Osteoporos Int 25:2279\u20132290","journal-title":"Osteoporos Int"},{"key":"351_CR22","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1056\/NEJMoa0809493","volume":"361","author":"SR Cummings","year":"2009","unstructured":"Cummings SR, San Martin J, McClung MR, Siris ES, Eastell R, Reid IR, Delmas P, Zoog HB, Austin M, Wang A et al (2009) Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 361:756\u2013765","journal-title":"N Engl J Med"},{"key":"351_CR23","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1359\/jbmr.0809010","volume":"24","author":"JP Brown","year":"2009","unstructured":"Brown JP, Prince RL, Deal C, Recker RR, Kiel DP, de Gregorio LH, Hadji P, Hofbauer LC, Alvaro-Gracia JM, Wang H et al (2009) Comparison of the effect of denosumab and alendronate on BMD and biochemical markers of bone turnover in postmenopausal women with low bone mass: a randomized, blinded, phase 3 trial. J Bone Miner Res 24:153\u2013161","journal-title":"J Bone Miner Res"},{"key":"351_CR24","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1359\/jbmr.090716","volume":"25","author":"DL Kendler","year":"2010","unstructured":"Kendler DL, Roux C, Benhamou CL, Brown JP, Lillestol M, Siddhanti S, Man HS, San Martin J, Bone HG (2010) Effects of denosumab on bone mineral density and bone turnover in postmenopausal women transitioning from alendronate therapy. J Bone Miner Res 25:72\u201381","journal-title":"J Bone Miner Res"},{"key":"351_CR25","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.bone.2013.10.006","volume":"58","author":"C Roux","year":"2014","unstructured":"Roux C, Hofbauer LC, Ho PR, Wark JD, Zillikens MC, Fahrleitner-Pammer A, Hawkins F, Micaelo M, Minisola S, Papaioannou N et al (2014) Denosumab compared with risedronate in postmenopausal women suboptimally adherent to alendronate therapy: efficacy and safety results from a randomized open-label study. Bone 58:48\u201354","journal-title":"Bone"},{"key":"351_CR26","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1097\/AOG.0b013e318291718c","volume":"121","author":"C Recknor","year":"2013","unstructured":"Recknor C, Czerwinski E, Bone HG, Bonnick SL, Binkley N, Palacios S, Moffett A, Siddhanti S, Ferreira I, Ghelani P et al (2013) Denosumab compared with ibandronate in postmenopausal women previously treated with bisphosphonate therapy: a randomized open-label trial. Obstet Gynecol 121:1291\u20131299","journal-title":"Obstet Gynecol"},{"key":"351_CR27","doi-asserted-by":"crossref","first-page":"3163","DOI":"10.1210\/jc.2016-1801","volume":"101","author":"PD Miller","year":"2016","unstructured":"Miller PD, Pannacciulli N, Brown JP, Czerwinski E, Nedergaard BS, Bolognese MA, Malouf J, Bone HG, Reginster JY, Singer A et al (2016) Denosumab or zoledronic acid in postmenopausal women with osteoporosis previously treated with oral bisphosphonates. J Clin Endocrinol Metab 101:3163\u20133170","journal-title":"J Clin Endocrinol Metab"},{"key":"351_CR28","unstructured":"Amgen (2014) Prolia\u00ae EU Summary of Product Characteristics. \nhttp:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/001120\/WC500093526.pdf\n\n. Accessed May 2016"},{"key":"351_CR29","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1007\/s00198-013-2515-2","volume":"25","author":"P Hadji","year":"2014","unstructured":"Hadji P, Felsenberg D, Amling M, Hofbauer LC, Kandenwein JA, Kurth A (2014) The non-interventional BonViva Intravenous Versus Alendronate (VIVA) study: real-world adherence and persistence to medication, efficacy, and safety, in patients with postmenopausal osteoporosis. Osteoporos Int 25:339\u2013347","journal-title":"Osteoporos Int"},{"key":"351_CR30","doi-asserted-by":"crossref","first-page":"868","DOI":"10.5414\/CP201931","volume":"51","author":"P Hadji","year":"2013","unstructured":"Hadji P, Klein S, H\u00e4ussler B, Kless T, Linder R, Rowinski-Jablokow M, Verheyen F, Gothe H (2013) The bone evaluation study (BEST): patient care and persistence to treatment of osteoporosis in Germany. Int J Clin Pharmacol Ther 51:868\u2013872","journal-title":"Int J Clin Pharmacol Ther"},{"key":"351_CR31","doi-asserted-by":"crossref","first-page":"2479","DOI":"10.1007\/s00198-015-3164-4","volume":"26","author":"P Hadji","year":"2015","unstructured":"Hadji P, Papaioannou N, Gielen E, Feudjo Tepie M, Zhang E, Frieling I, Geusens P, Makras P, Resch H, Moller G et al (2015) Persistence, adherence, and medication-taking behavior in women with postmenopausal osteoporosis receiving denosumab in routine practice in Germany, Austria, Greece, and Belgium: 12-month results from a European non-interventional study. Osteoporos Int 26:2479\u20132489","journal-title":"Osteoporos Int"},{"key":"351_CR32","unstructured":"Silverman SL, Siris E, Kendler DL, Belazi D, Brown JP, Gold DT, Lewiecki EM, Papaioannou A, Simonelli C, Quinn G et al (2015) Factors affecting persistence with denosumab (Prolia\u00ae) in postmenopausal women with osteoporosis: results from a prospective observational study. J Bone Miner Res 30 (Suppl 1). Available at \nhttps:\/\/www.asbmr.org\/education\/2015-abstracts\n\n. Accessed 19 June 2017"},{"key":"351_CR33","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1007\/s00198-014-2871-6","volume":"26","author":"SL Silverman","year":"2015","unstructured":"Silverman SL, Siris E, Kendler DL, Belazi D, Brown JP, Gold DT, Lewiecki EM, Papaioannou A, Simonelli C, Ferreira I et al (2015) Persistence at 12 months with denosumab in postmenopausal women with osteoporosis: interim results from a prospective observational study. Osteoporos Int 26:361\u2013372","journal-title":"Osteoporos Int"},{"key":"351_CR34","first-page":"P357","volume":"12","author":"E Boschitsch","year":"2015","unstructured":"Boschitsch E, Trinker N, Durchschlag E (2015) Persistence with denosumab in a menopause and osteoporosis clinic. IBMS BoneKEy 12:P357","journal-title":"IBMS BoneKEy"},{"key":"351_CR35","doi-asserted-by":"crossref","unstructured":"Morisky DE, Ang A, Krousel-Wood M, Ward HJ (2008) Predictive validity of a medication adherence measure in an outpatient setting. J Clin Hypertens 10:348\u2013354","DOI":"10.1111\/j.1751-7176.2008.07572.x"},{"key":"351_CR36","unstructured":"Bone HG, Brandi ML, Brown JP, Chapurlat R, Cummings SR, Czerwinski E, Fahrleitner-Pammer A, Kendler DL, Lippuner K, Roux C et al (2015) Ten years of denosumab treatment in postmenopausal women with osteoporosis: results from the FREEDOM extention trial. J Bone Miner Res 30 (Suppl 1). Available at \nhttps:\/\/www.asbmr.org\/education\/2015-abstracts\n\n. Accessed 19 June 201"},{"key":"351_CR37","doi-asserted-by":"crossref","first-page":"2773","DOI":"10.1007\/s00198-015-3234-7","volume":"26","author":"S Papapoulos","year":"2015","unstructured":"Papapoulos S, Lippuner K, Roux C, Lin CJ, Kendler DL, Lewiecki EM, Brandi ML, Czerwinski E, Franek E, Lakatos P et al (2015) The effect of 8 or 5 years of denosumab treatment in postmenopausal women with osteoporosis: results from the FREEDOM extension study. Osteoporos Int 26:2773\u20132783","journal-title":"Osteoporos Int"},{"key":"351_CR38","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/1471-2288-7-30","volume":"7","author":"R McCarney","year":"2007","unstructured":"McCarney R, Warner J, Iliffe S, van Haselen R, Griffin M, Fisher P (2007) The Hawthorne effect: a randomised, controlled trial. BMC Med Res Methodol 7:30","journal-title":"BMC Med Res Methodol"},{"key":"351_CR39","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1210\/jc.2006-1526","volume":"92","author":"PD Delmas","year":"2007","unstructured":"Delmas PD, Vrijens B, Eastell R, Roux C, Pols HA, Ringe JD, Grauer A, Cahall D, Watts NB, Improving Measurements of Persistence on Actonel Treatment (IMPACT) Investigators (2007) Effect of monitoring bone turnover markers on persistence with risedronate treatment of postmenopausal osteoporosis. J Clin Endocrinol Metab 92:1296\u20131304","journal-title":"J Clin Endocrinol Metab"},{"key":"351_CR40","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/s00198-009-0930-1","volume":"21","author":"FE Cotte","year":"2010","unstructured":"Cotte FE, Fardellone P, Mercier F, Gaudin AF, Roux C (2010) Adherence to monthly and weekly oral bisphosphonates in women with osteoporosis. Osteoporos Int 21:145\u2013155","journal-title":"Osteoporos Int"},{"key":"351_CR41","first-page":"38","volume":"12","author":"P Makras","year":"2012","unstructured":"Makras P, Vaiopoulos G, Lyritis GP, Greek National Medicine A (2012) 2011 guidelines for the diagnosis and treatment of osteoporosis in Greece. J Musculoskelet Neuronal Interact 12:38\u201342","journal-title":"J Musculoskelet Neuronal Interact"},{"key":"351_CR42","doi-asserted-by":"crossref","first-page":"2101","DOI":"10.1007\/s00198-015-3106-1","volume":"26","author":"A Wihlborg","year":"2015","unstructured":"Wihlborg A, Englund M, Akesson K, Gerdhem P (2015) Fracture predictive ability of physical performance tests and history of falls in elderly women: a 10-year prospective study. Osteoporos Int 26:2101\u20132109","journal-title":"Osteoporos Int"},{"key":"351_CR43","doi-asserted-by":"crossref","first-page":"340","DOI":"10.3904\/kjim.2011.26.3.340","volume":"26","author":"YH Lee","year":"2011","unstructured":"Lee YH, Song GG (2011) Efficacy and safety of monthly 150 mg oral ibandronate in women with postmenopausal osteoporosis: a systematic review and meta-analysis of randomized controlled trials. Korean J Intern Med 26:340\u2013347","journal-title":"Korean J Intern Med"},{"key":"351_CR44","first-page":"756","volume":"20","author":"EJ Campagna","year":"2014","unstructured":"Campagna EJ, Muser E, Parks J, Morrato EH (2014) Methodological considerations in estimating adherence and persistence for a long-acting injectable medication. J Manag Care Spec Pharm 20:756\u2013766","journal-title":"J Manag Care Spec Pharm"},{"key":"351_CR45","doi-asserted-by":"crossref","first-page":"824","DOI":"10.18553\/jmcp.2015.21.9.824","volume":"21","author":"LI Cheng","year":"2015","unstructured":"Cheng LI, Durden E, Limone B, Radbill L, Juneau PL, Spangler L, Mirza FM, Stolshek BS (2015) Persistance and compliance with osteoporosis therapies among women in a commercially insured population in the United States. J Manag Care Spec Pharm 21:824\u2013833 833a","journal-title":"J Manag Care Spec Pharm"}],"container-title":["Archives of Osteoporosis"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11657-017-0351-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11657-017-0351-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11657-017-0351-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,1,8]],"date-time":"2018-01-08T22:16:47Z","timestamp":1515449807000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11657-017-0351-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6,22]]},"references-count":45,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["351"],"URL":"https:\/\/doi.org\/10.1007\/s11657-017-0351-2","relation":{},"ISSN":["1862-3522","1862-3514"],"issn-type":[{"value":"1862-3522","type":"print"},{"value":"1862-3514","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,6,22]]},"article-number":"58"}}